UnitedHealth Group Q3 2026 Earnings: Profit Recovery Drives Higher Full-Year EPS Outlook

UnitedHealth Group reported third-quarter revenue of $112.7B, down modestly from $113.2B a year earlier, while GAAP diluted EPS rose to $4.56 from $2.59 and adjusted EPS increased to $4.69 from $2.92. The company raised its full-year adjusted EPS outlook to at least $20.50, citing improved execution at both UnitedHealthcare and Optum.

The central development was a substantial recovery in profitability despite declining membership in several government programs and lower consolidated revenue. Lower medical and operating cost ratios, along with a sharp Optum Health earnings improvement, more than offset the pressure from reduced Medicare Advantage, Medicaid and value-based care membership.

Earnings Snapshot

The Bigger Story

UnitedHealth’s quarter showed that its 2026 turnaround actions are translating into earnings recovery, but the recovery is being achieved against a smaller revenue and membership base.

Consolidated operating income rose 52% year over year to $6.6B even as revenue declined 0.4%. The improvement reflected tighter medical-cost management, pricing and benefit changes, lower administrative costs as a percentage of revenue, and a major improvement in Optum Health’s profitability.

That performance supports management’s argument that 2026 can serve as a reset year before returning to organic growth in 2027. However, the investment case still depends on whether UnitedHealth can restore sustainable membership growth and margins without relying excessively on benefit reductions, pricing actions, reserve development or shrinking less-profitable business lines.

The third-quarter medical care ratio benefited from $610M of net favorable prior-period reserve development related to 2026 dates of service. That reserve development helped the reported 88.4% medical care ratio, so investors should distinguish the underlying progress in pricing and utilization management from the quarter’s favorable reserve effect.

Revenue and Operating Performance

Consolidated revenue slipped to $112.7B from $113.2B. Premium revenue declined to $87.1B from $89.0B, while product revenue rose to $14.3B from $13.3B and service revenue increased to $10.2B from $9.8B.

The revenue mix reflects pressure in UnitedHealthcare’s risk-based insurance businesses and Optum Health, partly offset by growth in Optum Insight and Optum Rx.

UnitedHealthcare: Earnings Improved Despite Lower Membership

UnitedHealthcare revenue declined 1% to $86.3B, but operating earnings increased 57% to $2.8B. Its operating margin expanded to 3.3% from 2.1%.

The improvement was driven by benefit changes, pricing discipline, medical cost management and lower operating costs, according to the company. Those actions were especially important because membership continued to decline in core government programs.

UnitedHealthcare served 48.3 million medical members at quarter-end, down from 50.1 million a year earlier and 49.8 million at year-end 2025. Medicare Advantage membership was 7.6 million, down 935,000 from year-end 2025. Medicaid membership was 6.7 million, down 685,000 over the same period, reflecting continuing eligibility changes.

Within the commercial business, Employer & Individual revenue increased to $20.2B from $19.9B. Still, membership contracted by 165,000 during the quarter due to employer attrition. Management said national-account retention and persistency appear strong heading into 2027, while the mid-market selling season remains underway.

Medicare & Retirement revenue declined to $42.4B from $43.4B because of membership and product-mix changes. Community & State revenue was essentially flat at $23.7B, while quarter-end Medicaid enrollment declined by 85,000 sequentially.

Optum Health: Smaller Revenue Base, Much Better Margins

Optum Health remained the most consequential operating turnaround in the quarter. Revenue fell 10% year over year to $22.9B because the business served fewer value-based care patients in markets where it lacked enough value-based care presence to support its clinicians.

Yet operating earnings rose to $735M from $41M, and the operating margin improved to 3.2% from 0.2%. Management attributed the recovery to greater operating discipline and medical-cost management across its value-based care markets.

The result is an encouraging profit recovery, but it also demonstrates the trade-off in the current strategy. Optum Health is exiting or reducing exposure in areas that did not fit its value-based care model, which has reduced revenue and patient volume. The company said it sees opportunities to expand fully accountable care, professional capitation, shared-savings arrangements, home health, hospice, ambulatory surgery centers and post-acute care management.

Management continues to target a 6% to 8% Optum Health margin by 2028. It characterized 2027 as a year of further progress toward that objective rather than a period when the target will necessarily be reached.

Optum Insight and Optum Rx Added Stability

Optum Insight revenue rose 3% to $5.5B, while operating earnings increased 39% to $1.3B. Management said performance benefited from enhanced products, payment-integrity capabilities and operating efficiencies, while the business continues to invest in AI-enabled products.

Optum Insight’s reported 23.4% operating margin was well above other major businesses. Management said it is rationalizing lower-return products and contracts while investing in AI-based offerings, including claims and revenue-cycle tools. The business expects meaningful progress in 2027 and sees its larger growth opportunity building into 2028 and beyond.

Optum Rx revenue increased slightly to $39.9B, while operating earnings rose 11% to $1.7B. Adjusted scripts declined 5% to 393 million, largely due to membership declines at UnitedHealthcare and other customers. Still, the segment benefited from biosimilar adoption and operating improvements.

Management said more than half of Optum Rx membership is now from external, non-UnitedHealthcare customers. It also reported high client retention and continued growth in specialty pharmacy, where specialty volume increased despite lower overall script volume.

Profitability and Margins

The quarter’s headline was margin recovery. Consolidated operating margin increased to 5.8% from 3.8%, while net margin rose to 3.6% from 2.1%.

The medical care ratio improved by 150 basis points to 88.4%. Management attributed the decline to medical-cost management, pricing discipline, benefit design changes and care-delivery enhancements. However, the ratio also included $610M of favorable prior-period reserve development. That item improved reported costs in the quarter and should be considered when assessing the durability of the lower medical-cost ratio.

The operating cost ratio declined to 12.8% from 13.5%, reflecting realized operating efficiencies. UnitedHealth said those savings were partly offset by accelerating investments in technology, processes, people and consumer and clinician experience improvements.

GAAP diluted EPS was $4.56, while adjusted EPS was $4.69. Adjusted EPS excludes intangible amortization, portfolio divestiture and South American impacts, restructuring items and related tax effects.

Demand, Customers and Pricing

Management’s commentary suggests that medical-cost trends remain a key constraint, particularly in commercial insurance. The company said commercial trend continues above its initial expectation of 11%, driven by specialty drugs, clinician pricing, acute-care intensity and the No Surprises Act independent dispute resolution process.

Management said dispute-resolution awards in certain regions can approach 6% of total medical spending. The company argued that the process is contributing to affordability pressure, though any policy change remains outside its control.

In Medicaid, management said utilization trends remain elevated in behavioral health, specialty pharmacy, home and community-based services, and inpatient care. It expects 2026 core Medicaid margins to be moderately better than negative 1%, with improvement expected as state rates are updated and internal cost-management initiatives gain traction.

For Medicare Advantage, the company expects to finish 2026 near the upper end of its 2% to 4% margin range. Its 2027 strategy remains focused on higher-value HMO, dual-eligible special needs and chronic-condition special needs plans, rather than broad-based expansion across all products.

What is UnitedHealth Group’s guidance for full-year 2026?

UnitedHealth raised its full-year 2026 outlook and now expects:

• ·GAAP diluted EPS of at least $19.50
• ·Adjusted diluted EPS of at least $20.50

Management said the updated outlook reflects performance through the third quarter, balanced by expected investments in the final months of 2026.

The company did not provide formal 2027 financial guidance. Management said it views the lower end of its long-term 13% to 16% growth target as a reasonable starting point for 2027, while cautioning that it expects continued investments in modernization, policy reforms, UnitedHealthcare and Optum Insight.

Management also expects to approach a 40% debt-to-capital ratio by year-end. For Optum Health, the company reiterated its objective of reaching a 6% to 8% operating margin by 2028.

Balance Sheet, Cash Flow and Capital

Cash flow from operations was $5.1B in the third quarter, equal to 1.2 times net income. For the first nine months of 2026, operating cash flow was $25.1B, up from $18.6B a year earlier.

Cash and short-term investments totaled $28.5B at September 30, compared with $28.1B at year-end 2025. Long-term debt was $68.7B, down from $72.3B at year-end.

The debt-to-capital ratio was 41.7%, modestly above 41.2% at the end of the second quarter. Management continues to target approximately 40% by year-end.

UnitedHealth repurchased $5.0B of stock and paid $6.2B in dividends through the first nine months of the year. It expects dividends to exceed $8B for full-year 2026.

What Investors Should Watch

1. Medical-cost trends and reserve development

The 88.4% medical care ratio was a major contributor to earnings recovery, but it included $610M of favorable reserve development. Investors should monitor whether medical costs remain controlled without similar reserve benefits, particularly in commercial, specialty pharmacy and acute-care utilization.

2. Medicare Advantage enrollment and margins

Medicare Advantage enrollment has declined sharply since year-end 2025, even as profitability improves. The key 2027 question is whether UnitedHealth can return to durable growth in HMO, dual-eligible and chronic-condition plans without sacrificing the pricing and benefit discipline that supported 2026 margins.

3. Optum Health’s path toward 6% to 8% margins

Optum Health’s earnings rebound was substantial, but revenue declined 10% and the segment’s 3.2% operating margin remains below its long-term target. Continued margin improvement, patient growth in accountable-care models and evidence that current clinical investments generate returns will be central to the turnaround thesis.

4. Commercial pricing and No Surprises Act pressure

Management said commercial trend remains above 11%, with dispute-resolution awards and specialty drug costs adding pressure. The company’s ability to price appropriately for 2027 and improve commercial margins will be important, especially if utilization remains elevated.

5. Medicaid rate adequacy

UnitedHealth expects core Medicaid margins to remain negative in 2026, though moderately better than negative 1%. Progress in state rate updates and medical-cost management will determine whether the business can return to targeted profitability by 2028, as management expects.

AlgovestIQ Takeaway

UnitedHealth delivered a materially stronger profit quarter than the year-ago period, with operating earnings up more than 50% and adjusted EPS up 61%. The company’s raised 2026 outlook reflects genuine improvement in medical-cost management, operating efficiency and Optum Health execution.

The main positive is that profitability improved across both UnitedHealthcare and Optum. UnitedHealthcare expanded margins despite lower revenue, while Optum Health moved from near-breakeven profitability to a 3.2% operating margin. Optum Insight and Optum Rx also posted earnings growth, providing diversification beyond the insurance business.

Still, revenue growth and membership trends remain unresolved. Medicare Advantage, Medicaid and Optum Health patient volumes have declined, and commercial medical trends remain elevated. The recovery is currently more about restoring margins and reshaping the portfolio than demonstrating broad-based top-line momentum.

The central investment question is whether UnitedHealth can convert its 2026 cost and portfolio actions into sustainable growth beginning in 2027. Evidence of stabilized membership, durable medical-cost improvement without favorable reserve development, continued Optum Health margin expansion and successful commercial repricing would strengthen that case. Continued enrollment contraction or persistent medical-cost pressure would make the company’s long-term growth target more difficult to achieve.